Novartis touts older cancer drug for MS in attack on Roche's Ocrevus

Novartis said on Wednesday that an older leukaemia drug it is re-purposing for multiple sclerosis halted disease activity in many patients during the first two years of injections as the Swiss drugmaker takes aim at Roche's lucrative Ocrevus infusion.

from Reuters: Health News https://ift.tt/3bZmt9u